论文部分内容阅读
42例经内窥镜证实的反流性食道炎进行单盲-双盲多中心研究。病人随机接受甲氰咪胍400mg一日4次,或硫糖铝1 g一日4次,为期8周。两组病人均为21例,病人的特征呈可比性。治疗4周后,最常见症状如胸骨后烧灼感和食道疼痛改善,硫糖铝组和甲氰咪胍组分别为41%(7/17)和53%(10/17)。硫糖铝组4例和甲氰咪胍组6例,8周后咽下困难均消失。硫糖铝组和甲氰咪胍组8周后食道损害愈合率分别为31%和14%;食道损害改善分别为68%和76%。然而,据Stvary-Miller标准分度评价改善情
42 cases of endoscopic confirmed reflux esophagitis single-blind - double-blind multicenter study. The patients were randomized to receive either cimetidine 400 mg four times daily or sucralfate 1 g four times daily for eight weeks. Two groups of patients were 21 cases, the patient’s characteristics were comparable. After 4 weeks of treatment, the most common symptoms such as retrosternal burning and esophageal pain were improved, with sucralfate and cimetidine 41% (7/17) and 53% (10/17), respectively. Four cases of sucralfate group and six cases of cimetidine group, dysphagia disappeared after 8 weeks. The healing rates of esophageal damage after sucralfate and cimetidine were 31% and 14% respectively after 8 weeks; esophageal lesions were improved by 68% and 76% respectively. However, according to the Stvary-Miller standard graduation evaluation to improve the situation